Lumos Pharma Inc

Lumos Pharma — Technical Presentation (November 2022)

55 slides from Lumos Pharma's technical presentation, Nov 14, 2022

  1. Slide 1: Interim Analysis OraGrowtH210 & OraGrowtH212

    1 Interim Analysis OraGrowtH210 & OraGrowtH212 November 14, 2022

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. (“Lumos,” “we,” “us” and “our”), and such content should be considered “Confidential Information” and covered by your confidentiality obligations to Lumos. This presentation is made

  3. Slide 3: Investment Highlights

    3 Investment Highlights Lead asset targeting children with growth disorders PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Positi

  4. Slide 4: Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD

    4 Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD SAEs = Serious adverse events AEs = Adverse events • AHV of 8.6 cm at 6-months on 1.6 mg/kg/day LUM-201, in line with 8.3 cm expected in PEM+ PGHD • LUM-201 AHVs are sustained & converge with rhGH AHVs at 12-month treatment inter

  5. Slide 5: OraGrowtH210 Trial: Phase 2 Trial Evaluating Oral LUM-201 in Moderate PGHD

    OraGrowtH210 Trial Phase 2 Trial Evaluating Oral LUM-201 in Moderate PGHD

  6. Slide 6: LUM-201 Stimulates Natural Growth Hormone Secretion

    6 LUM-201 Stimulates Natural Growth Hormone Secretion • LUM-201 is an oral GH secretagogue* • Acts on specific receptors in hypothalamus and pituitary to stimulate release of GH1 • Increases the amplitude of natural pulsatile GH secretion2,3 • LUM-201 stimulated GH release regulated by natural GH/IG

  7. Slide 7: PEMs Enrich Trials for Patients Likely to Respond to LUM-201

    7 PEMs Enrich Trials for Patients Likely to Respond to LUM-201 (PEM+) PEM-positive = PGHD patients with baseline IGF-1 > 30 ng/ml & stimulated GH ≥ 5 ng/ml 1 Bright 2021 JES HP-GH axis – hypothalamic pituitary growth hormone axis 2 Blum 2021 JES Responders Non-Responders ~ PEMs = Predictive Enrichme

  8. Slide 8: OraGrowtH210 Trial: Phase 2 Trial in PGHD

    8 OraGrowtH210 Trial: Phase 2 Trial in PGHD n = 20 Daily rhGH injection n = 20 LUM-201: 3.2 mg/kg/day n = 20 LUM-201: 1.6 mg/kg/day n = 20 LUM-201: 0.8 mg/kg/day • n = 80 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • ~40 trial sites US &

  9. Slide 9: Historical Data for rhGH Growth Rates in Moderate PGHD Patients

    9 Historical Data for rhGH Growth Rates in Moderate PGHD Patients rhGH 0204 rhGH GeNeSIS1 rhGH iPGHD2 rhGH KIGS3 0 4 8 12 16 20 n=3075 8.58 n=100 8.30 n=433 8.29 n=11 8.80 A n n u a li z e d H e ig h t V e lo c it y ( c m /y r) • GeNeSIS1, iPGHD2, and KIGS3 AHV from 12 months of rhGH • Merck 0204 AH

  10. Slide 10: OraGrowtH210 Interim Analysis: AHV at 6 Months

    10 OraGrowtH210 Interim Analysis: AHV at 6 Months (41 Subjects) • LUM-201 1.6 mg/kg/day cohort grew 8.6 cm/yr, in line with the expected rate of 8.3 cm/yr based on prior data • rhGH cohort grew at a much faster rate than expected or previously reported in moderate PGHD population • Cohort baseline d

  11. Slide 11: LUM-201 Growth in Trial is Consistent with Historical Precedent

    11 LUM-201 Growth in 210 Trial is Consistent with Historical Precedent The rhGH arm in 210 trial showed growth inconsistent with multiple historical studies in this PGHD population Sources: 1 Blum et al JES 2021, 2 Lechuga-Sancho et al JPEM 2009, 3 Ranke et al JCEM 2010, 4 Bright et al JES 2021. Con

  12. Slide 12: OraGrowtH210 Trial rhGH Cohort Grew More than Historical Norms

    12 OraGrowtH210 Trial rhGH Cohort Grew More than Historical Norms in Moderate PGHD Patient Population Unprecedented rhGH growth response in OraGrowtH 210 in moderate PGHD likely due to outlier & small sample size Expect larger N from fully enrolled dataset to reduce impact of growth outliers 1) Rose

  13. Slide 13: OraGrowtH210 Trial rhGH Cohort Grew More than Historical Norms

    13 OraGrowtH210 Trial rhGH Cohort Grew More than Historical Norms in Moderate PGHD Patient Population Unprecedented rhGH growth response in OraGrowtH 210 in moderate PGHD likely due to outlier & small sample size Expect larger N from fully enrolled dataset to reduce impact of growth outliers 1) Rose

  14. Slide 14: Key Baseline Characteristics that Predict Better AHV With rhGH Treatment

    14 Key Baseline Characteristics that Predict Better AHV With rhGH Treatment of PGHD Patients Historical data from multiple peer-reviewed scientific publications demonstrate the following metrics as key predictors of first-year growth • Baseline Age • Age is the top predictor of growth on treatment •

  15. Slide 15: Baseline Characteristics by Cohort

    15 LUM-201 0.8 mg Mean (SD) N=11 LUM-201 1.6 mg Mean (SD) N=10 LUM-201 3.2 mg Mean (SD) N=10 rhGH Mean (SD) N=10 Age (months) 95.5 (28.2) 99.3 (28.3) 96.1 (21.7) 90.3 (26.7) Height (cm) 113.8 (12.6) 114.6 (9.6) 113.8 (8.8) 111.6 (11.9) Height SDS -2.31 (0.32) -2.35 (0.62) -2.30 (0.48) -2.29 (0.43) M

  16. Slide 16: Baseline Comparison of 1.6mg Arm to Control Arm

    16 Baseline Comparison of 1.6mg Arm to Control Arm LUM-201 1.6 mg Mean (SD) N=10 rhGH Mean (SD) N=10 Age in months 99.3 (28.3) 90.3 (26.7) Height in cm 114.6 (9.6) 111.6 (11.9) Height SDS -2.35 (0.62) -2.29 (0.43) Min Height SDS -3.90 -3.07 IGF-1 SDS -1.17 (0.72) -1.37 (0.48) Max IGF-1 SDS -0.3 -0.7

  17. Slide 17: Growth Outliers in the rhGH Cohort: Subjects under 5

    17 Age (years) Growth Outliers in the rhGH Cohort: 2/3 Subjects under 5 Randomized to rhGH 1 Ranke, et al 2010 JCEM OraGrowtH210 youngest subjects in rhGH cohort at 6-months AHV P lines = Percentiles “Before” line marks height velocity before GH therapy First-year Growth on rhGH for Moderate PGHD KI

  18. Slide 18: Baseline Characteristics by Cohort (Larger N)

    18 LUM-201 0.8 mg Mean (SD) N=14 LUM-201 1.6 mg Mean (SD) N=15 LUM-201 3.2 mg Mean (SD) N=14 rhGH Mean (SD) N=15 Age (months) 99.1 (28.3) 98.4 (28.6) 92.9 (22.6) 94.1 (23.7) Height (cm) 115.1 (12.5) 114.6 (11.2) 112.4 (9.2) 113.4 (10.6) Height SDS -2.32 (0.3) -2.31 (0.5) -2.32 (0.4) -2.25 (0.4) Max

  19. Slide 19: Baseline Comparison of rhGH Arm at N=15 and N=10

    19 Baseline Comparison of rhGH Arm at N=15 and N=10 rhGH Mean (SD) N=15 rhGH Mean (SD) N=10 Age in months 94.1 (23.7) 90.3 (26.7) Height in cm 113.4 (10.6) 111.6 (11.9) Height SDS -2.25 (0.4) -2.28 (0.43) Max Height SDS -1.73 -1.73 IGF-1 SDS -1.32 (0.46) -1.37 (0.48) Max IGF-1 SDS -0.7 -0.7 MPH in c

  20. Slide 20: Data: LUM-201 Demonstrates Durable Response to 9 Months

    20 210 Data: LUM-201 Demonstrates Durable Response to 12 Months • LUM-201 growth rates consistent from 6 to 12 months • rhGH growth rates decline more from 6 to 12 months, narrowing the AHV ∆ between the arms at 12 months • A Phase 3 non-inferiority trial is expected to be a 12-month study in a much

  21. Slide 21: OraGrowtH212 Trial: PK/PD Trial Evaluating Oral LUM-201 in PGHD

    OraGrowtH212 Trial PK/PD Trial Evaluating Oral LUM-201 in PGHD

  22. Slide 22: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD

    22 • n = up to 24 • Open-label study • PGHD patients • rhGH-treatment naïve • Dosing to near-adult height • Single, specialized clinical site • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD Primary Endpoints: • Assess LUM-201 effect on endoge

  23. Slide 23: OraGrowtH212 & OraGrowtH210 Comparative AHVs at 6 Months

    23 OraGrowtH212 & OraGrowtH210 Comparative AHVs at 6 Months • OraGrowtH212 Trial results showed a similar growth rate to OraGrowtH210 Trial • Anticipate fully enrolled datasets and larger N from both trials to strengthen these results • Anticipate larger Phase 3 trial to further support the LUM- 201

  24. Slide 24: OraGrowtH212 Data Demonstrate Durable Response

    24 OraGrowtH212 Data Demonstrate Durable Response • OraGrowth212 data also demonstrate growth is durable out to 12 months • This separate study supports the narrowing of the AHV difference seen in the 210 trial as subjects approach 12 months on treatment • A Phase 3 non-inferiority trial is expected

  25. Slide 25: OraGrowtH210 & OraGrowtH212 Interim Data Combined

    25 OraGrowtH210 & OraGrowtH212 Interim Data Combined • Post-hoc analysis of combined data conducted to determine optimal dose for Phase 3 • Comparable mean AHVs for top 2 LUM-201 doses seen at 6,9, and 12 months • Combined interim data supports selection of 1.6 mg/kg/day dose for pivotal Phase 3 tri

  26. Slide 26: Safety and Tolerability

    Safety and Tolerability

  27. Slide 27: Interim Safety and Tolerability Profile

    27 Interim Safety and Tolerability Profile • We believe LUM-201 will demonstrate a favorable safety profile as data from both OraGrowtH trials to date show comparable safety and tolerability to the rhGH subjects in the trials. • No meaningful safety signals to date o In laboratory values o In Advers

  28. Slide 28: Financials

    Financials

  29. Slide 29: Lumos Pharma Financial Information as of September 30, 2022

    29 Lumos Pharma Financial Information as of September 30, 2022 Values in USD Cash $73.7M Debt $0 Shares Outstanding 8.4M Cash Use in Q4 2022 $8.5-$9.5M Fiscal Year End December 31 LUMO Cash balance to support current operations into 2Q 2024, Beyond primary outcome data readouts for OraGrowtH210 and

  30. Slide 30: Conclusions

    Conclusions

  31. Slide 31: Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD

    31 Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD SAEs = Serious adverse events AEs = Adverse events • AHV of 8.6 cm at 6-months on 1.6 mg/kg/day LUM-201, in line with 8.3 cm expected in PEM+ PGHD • LUM-201 AHVs are sustained & converge with rhGH AHVs at 12-month treatment inte

  32. Slide 32: Interim Analysis Supplemental Materials

    Interim Analysis Supplemental Materials

  33. Slide 33: Safety Profile at Interim Analysis for OraGrowtH210 Trial

    33 Safety Profile at Interim Analysis for OraGrowtH210 Trial 66 subjects randomized to date with safety data available for 58 subjects at interim analysis PEM Dose* 0.8 mg/kg 1.6 mg/kg 3.2 mg/kg ALL LUM-201 rhGH 34 mcg/kg N = 86 14 15 14 43 15 Number of AEs 29 31 45 38 114 21 Subjects with AE (%) 17

  34. Slide 34: Specific AEs – No meaningful signal

    34 Specific AEs – No meaningful signal 66 subjects randomized to date with safety data available for 58 subjects at interim analysis PEM Dose* N=86 0.8 N=14 1.6 N=15 3.2 N=14 ALL N=43 rhGH N=15 Arthralgia 1 (1.2%) 1 (7.1%) 2 (13.3%) 2 (14.3%) 5 (11.6%) 1 (6.7%) Myalgia 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (

  35. Slide 35: Specific AEs - No meaningful signal

    35 Specific AEs - No meaningful signal 66 subjects randomized to date with safety data available for 58 subjects at interim analysis PEM Dose N=86 0.8 N=14 1.6 N=15 3.2 N=14 ALL N=43 rhGH N=15 Asthma 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (7.1%) 1 (2.3%) 0 (0.0%) Hyperhydrosis 2 (2.3%) 0 (0.0%) 0 (0.0%) 0 (0.

  36. Slide 36: Laboratory Shifts: No meaningful signal

    36 * Percentages calculated based on subjects with both baseline and post-baseline assay data ** Bidirectional shifts diminish any concern Laboratory Shifts: No meaningful signal 66 subjects randomized to date with safety data available for 58 subjects at interim analysis* 0.8 mg/kg N=14 1.6 mg/kg N

  37. Slide 37: Baseline Characteristics for Top Dose Cohorts in 210 and 212 Studies

    37 Baseline Characteristics for Top Dose Cohorts in 210 and 212 Studies 210 1.6 mg/kg N=10 210 3.2 mg/kg N=10 212 1.6 mg/kg N=5 212 3.2 mg/kg N=5 Age (Mos) 99.3 96.1 93.6 91.0 Height SDS -2.35 -2.30 -1.99 -2.26 IGF-1 SDS -1.17 -1.39 -1.11 -0.83 Delta MPH 1.76 1.96 0.57 0.70 BA delay yr 1.91 2.19 1.5

  38. Slide 38: Growth Outliers in the rhGH Cohort: Subjects under 5

    38 Age (years) Growth Outliers in the rhGH Cohort: 2/3 Subjects under 5 Randomized to rhGH Ranke, et.al. 2010 JCEM OraGrowtH210 Top growers in rhGH cohort at 6-months AHV outlier P lines = Percentiles “Before” line marks height velocity before GH therapy

  39. Slide 39: Ranke Model is the Gold Standard in Growth Prediction for GHD

    39 Ranke Model is the Gold Standard in Growth Prediction for GHD PHV = 14.55 + [-1.37 X (ln max GH stim)] + (-0.32 X Age) + (0.32 X BWt SDS) + (-0.5457) + (-0.4 X HtSDS-MPH SDS) + (0.29 X Wt SDS) [-1.37 X (ln max GH stim)]• Parameter Rank 1st A measure of how GHD subject is by stim test value (-0.32

  40. Slide 40: What does Ranke Model Predict about Growth in our Trial Cohorts?

    40 What does Ranke Model Predict about Growth in our Trial Cohorts? Growth predicted using baseline characteristics of subjects enrolled in OraGrowtH210 • Our assessment is that the key baseline characteristics, particularly age, between cohorts are enough to bias the rhGH cohort towards more growth

  41. Slide 41: What does Ranke Model Predict about Growth in our Trial Cohorts?

    41 What does Ranke Model Predict about Growth in our Trial Cohorts? Growth predicted using baseline characteristics of subjects enrolled in OraGrowtH210 • 1.6 mg/kg cohort is aligned with Ranke model predictions at all time points • rhGH cohort grows faster than predicted likely due to outliers • Th

  42. Slide 42: Additional Supplemental Materials

    42 Additional Supplemental Materials

  43. Slide 43: Management – Significant Clinical Development and Commercial Experience

    43 Management – Significant Clinical Development and Commercial Experience Richard Hawkins Chairman & CEO Developed Growth Hormone (GH) Receptor Antagonist for Acromegaly at Sensus (sold to Pfizer). Built one of the first contract recombinant protein manufacturing facilities (Covance Biotechnology).

  44. Slide 44: LUM-201 Program Pipeline

    44 LUM-201 Program Pipeline Study Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren) In PGHD Phase 2 Ongoing Phase 2 trial: Interim analysis obtained Primary outcome data 2H 2023 Long-term extension Proposed long-term extension study for OraGrowtH Trials PK/PD trial Ongoing PK/PD trial

  45. Slide 45: PGHD is ~35% of the $3.4B Pediatric Recombinant Growth Hormone Market

    45 PGHD is ~35% of the $3.4B Pediatric Recombinant Growth Hormone Market • Pediatric rhGH market projected to grow ~8% per year* • Well characterized market with established reimbursement mechanisms • Current SOC consists of daily injectables; expected to convert to weekly injectables • Pediatric rh

  46. Slide 46: Market Research: Daily Oral Therapeutic Preferred Over Weekly Injectable

    46 Market Research: Daily Oral Therapeutic Preferred Over Weekly Injectable 1 Initial Primary Research of PGHD Market conducted for Lumos by Triangle Insights. Physicians N = 20. Caregivers N = 9. 75% 25% Interview Question: If a daily oral secretagogue and a weekly rhGH injectable product were both

  47. Slide 47: Pediatric Growth Hormone Deficiency (PGHD) – Conversion from Injection to Oral

    47 Pediatric Growth Hormone Deficiency (PGHD) – Conversion from Injection to Oral 1 GlobalData EpiCast Report for Growth Hormone Deficiency Epidemiology forecast to 2026 2 Rosenfeld 2008 Endocrine Practice 3 Cutfield 2011 PLOS ONE • Inadequate secretion of growth hormone during childhood • Majority

  48. Slide 48: Significant Prior Clinical Experience with LUM-201 – Both Pediatric and Adult

    48 Significant Prior Clinical Experience with LUM-201 – Both Pediatric and Adult • Multiple trials were conducted by Merck prior to Lumos acquisition of LUM-201 in July 2018 • Six large-scale adult studies (n ~1,000) o In every adult indication, IGF-1 and/or GH levels were meaningfully increased fro

  49. Slide 49: Study 020 Post-Hoc Analysis: PEM-Positive Patients Responsive to LUM-201

    49 Study 020 Post-Hoc Analysis: PEM-Positive Patients Responsive to LUM-201 • Naïve PGHD, Study 020 o N=68; three arms o Placebo patients switched to rhGH at 6 months o Annualized growth shown for each arm • PEM-positive subset: o LUM-201 0.8 mg/kg not statistically different from rhGH o Dose respon

  50. Slide 50: PK/PD: Evidence of a PK and PD Dose Response in Healthy Volunteers

    50 PK/PD: Evidence of a PK and PD Dose Response in Healthy Volunteers PharmacodynamicsPharmacokinetics Dose response to 5.6 mg/kg PGHD dose equivalent* PD plateau possible ≥ 2.8 mg/kg PGHD dose equivalent* Higher LUM-201 doses produce higher plasma concentrations of LUM-201 & GH up to PD plateau PD

  51. Slide 51: PK/PD Data Show LUM-201 Pulsatile MOA & Potential Efficacy in PGHD Patients

    51 PK/PD Data Show LUM-201 Pulsatile MOA & Potential Efficacy in PGHD Patients * Merck Study 020 patient subset. Cassorla, F. PEM Positive PEM Negative Patient A Patient B Patient C Baseline 6months Baseline 6months Baseline 6months IGF-1 (ng/ml) 182 231 53 72 17 15 Q20m 24h GH Mean (ng/ml) 3.4 6.3

  52. Slide 52: More GH Released from LUM-201 Stim than from Standard Stim Test Agents

    52 More GH Released from LUM-201 Stim than from Standard Stim Test Agents 0 2 4 6 8 10 12 GH to Standard GH Stimulation Tests (ng/mL) 2 4 6 8 20 40 60 80 G H t o S in g le D o s e L U M -2 0 1 ( n g /m L ) 68 children with growth hormone deficiency All had 2 standard GH stimulation tests • Standard

  53. Slide 53: Exclusivity and Barriers with Orphan Designation and IP

    53 Exclusivity and Barriers with Orphan Designation and IP With potential pediatric extensions, LUM-201 is eligible for: Plan to seek Orphan Drug Designation in Japan Use of LUM-201 in PGHD and other GHD indications based on PEM strategy Patents for LUM-201 in GHD with protection through 2036 • Pate

  54. Slide 54: Study of Oral LUM-201 in Non-Alcoholic Fatty Liver Disease (NAFLD)

    54 • n = 10 • Adult NAFLD subjects with relative GH/IGF-1 deficiency • Open-label • Single-site pilot study • 6-month dosing Study of Oral LUM-201 in Non-Alcoholic Fatty Liver Disease (NAFLD) Mass General Investigator-Initiated Phase 2 Pilot Trial Primary Objective: • Determine changes in intra- hep

  55. Slide 55: LUM-201 Deal Terms

    55 LUM-201 Deal Terms *Milestone figures are maximum, may be less depending on development stage achieved and total net sales up to $1B Partner Upfront Payment Development Milestones* Sales Milestones* Worldwide Sales Royalties, Combined Ammonett $3.5M $17M first indication $14M second indication $5

Lumos Pharma — Technical Presentation (November 2022) on 6ix